ClinicalTrials.gg
CompletedNCT03386591Updated Mar 9, 2018

Comparison of Naloxone Pharmacokinetics

A Phase 1 interventional study of Naloxone and Mucosal atomization device and syringe in Opioid-use Disorder, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-09.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA) — 4 open to participants now, 4 under way, none of them phase 3. Opioid-Related Disorders · National Institute on Drug Abuse (NIDA).

Enrollment
20th of 70
30 · median 4
Started
2018
the only one that year
Phase 1
22 of 76
3 open now
Registered
68th of 76
by date

Among the 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA), this one is the 20th largest by enrollment of the 70 interventional ones that give a count, is the only one that started in 2018, is one of 22 in phase 1, and was the 68th registered.

Opioid-Related Disorders

1,475 studies on the registry are indexed under Opioid-Related Disorders; 292 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

4 of the 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 212 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 75 (35%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Opioid-Related Disorders by National Institute on Drug Abuse (NIDA), or all of them as a file.
02

Study summary

Intranasal (IN) naloxone administration is an effective alternative to intravenous (IV) or intramuscular (IM) naloxone by emergency medical services for opioid overdoses and has been used successfully for this purpose as reported in clinical observational studies and a randomized controlled trial. Most of the published clinical studies concerning IN administration used an improvised kit of 2 mg naloxone/2 mL saline and a mucosal atomizer device (MAD), which is not FDA-approved for this indication. Pharmacokinetic (PK) data using these kits is not available in the published literature. This study is designed to determine the PK of naloxone following one and two IN administrations using the improvised kits compared to 2 and 4 mg delivered IN using the FDA-approved Narcan nasal spray device and 2 mg administered IM using the Evzio autoinjector.

03

Conditions studied

  • Opioid-use Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18 to 55 years of age, inclusive
  • Provide written
  • ranging from 18 to 32 kg/m2, inclusive
  • Adequate venous access
  • No concurrent medical conditions determined by medical history, physical examination, clinical laboratory examination, vital signs, and 12-lead
  • Male subjects must agree to use an acceptable method of with female partners as well as not to donate sperm from the screening visit until 90 days after the last study drug administration
  • Female subjects of must agree to use an acceptable method of birth control from the start of screening until 30 days after the last study drug administration. Oral contraceptives are prohibited
  • Agree not to ingest alcohol, drinks containing xanthine >500 mg/day (e.g., Coca Cola®, coffee, tea, etc.), or grapefruit/grapefruit juice or participate in strenuous exercise 72 hours prior to admission through the last blood draw of the study

Exclusion criteria

Exclusion Criteria:

  • Contact site directly for more information
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Mucosal Atomization (1 administration)

    One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)

    Drug: Naloxone · Device: Mucosal atomization device and syringe

  • Experimental
    Mucosal Atomization (2 administrations)

    Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart

    Drug: Naloxone · Device: Mucosal atomization device and syringe

  • Experimental
    Narcan 2mg

    One Intranasal administration of 2 mg naloxone using Narcan nasal spray

    Drug: Naloxone · Device: Narcan

  • Experimental
    Narcan 4mg

    One Intranasal administration of 4 mg naloxone using Narcan nasal spray

    Drug: Naloxone · Device: Narcan

  • Experimental
    Intramuscular auto injector

    One Intramuscular administration of 2 mg naloxone using Evzio auto-injector

    Drug: Naloxone · Device: Intramuscular Auto Injector

Interventions

  • Comparing pharmacokinetics of naloxone

  • DeviceMucosal atomization device and syringe

    Injection

  • DeviceNarcan

    Nasal Spray

  • DeviceIntramuscular Auto Injector

    Intramuscular injection

    Also known as: Evzio

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters of naloxone

    Maximum plasma concentration, time of maximum observed concentration and area under the concentration-time curve

    Time frame: 11 days

Secondary outcomes

  1. Safety Assessments

    Number of participants with AEs, vital signs, ECG, laboratory changes and nasal irritation following the administration of naloxone.

    Time frame: 16 days

07

Study locations

1 site
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Feb 2018, 1 month.

Of 54 non-industry phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 1 month is below that.

Counting every sponsor, half of 78 studies reached it within 19 months; a quarter within 9 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 29, 2017
StartActual
Jan 3, 2018
Primary completionActual
Feb 8, 2018
CompletionActual
Mar 6, 2018
Last update
Mar 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03386591
Responsible party
Sponsor
First posted
Dec 29, 2017
Start date
Jan 3, 2018
Primary completion
Feb 8, 2018
Completion
Mar 6, 2018
Last update
Mar 9, 2018

Study contacts

Debra Kelsh, MD
principal investigator · Vince and Associates Clinical Research

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion